Oncology Molecular Diagnostic Market Set for Strong Growth as Precision Medicine and Liquid Biopsy Adoption Accelerate
Oncology Molecular Diagnostic Market Overview
The Oncology Molecular Diagnostic Market is gaining momentum as healthcare systems increasingly shift toward precision oncology, biomarker-based treatment selection, early cancer detection, and molecular monitoring. Oncology molecular diagnostics enable clinicians and researchers to identify genetic and molecular characteristics of tumors, helping support more personalized treatment decisions and improving the understanding of disease progression and treatment response.
The market is being driven by the increasing global burden of cancer, growing adoption of targeted therapies, rising demand for companion diagnostics, and continuous advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), digital PCR, fluorescence in-situ hybridization, and other molecular testing technologies. The expansion of precision medicine is particularly important because treatment decisions increasingly depend on identifying specific genomic alterations and biomarkers rather than relying exclusively on tumor location or conventional pathology.
Liquid biopsy represents another major opportunity. Tests based on circulating tumor DNA (ctDNA) can provide molecular information through a blood sample and have potential applications in treatment selection, disease monitoring, minimal residual disease assessment, and recurrence surveillance. The FDA's Oncology Center of Excellence identifies liquid biopsy and multiomic biomarkers as active areas of regulatory-science research, including approaches for monitoring treatment resistance and validating biomarkers.
Growing pharmaceutical investment in targeted cancer therapies is also increasing the need for companion diagnostics. As more therapies are developed around specific molecular targets, diagnostic testing becomes increasingly important for identifying patients most likely to benefit from treatment. This creates opportunities for diagnostic companies to develop integrated testing platforms combining genomic analysis, artificial intelligence, bioinformatics, and clinical interpretation.
* Explore Investment Opportunities: https://www.maximizemarketresearch.com/request-sample/112479/
U.S. Market Trends and Investment
The United States remains one of the most important markets for oncology molecular diagnostics because of its advanced healthcare infrastructure, large cancer research ecosystem, strong biotechnology sector, and established regulatory pathway for molecular diagnostic devices. In 2025, investment continued to flow into liquid biopsy and precision-oncology technologies. GeneCentric Therapeutics announced an $8 million Series C financing in June 2025 to commercialize its GenomicsNext platform, which combines gene-expression measurements with DNA-variant detection from circulating tumor DNA in a single liquid-biopsy sample.
Myriad Genetics also continued expanding its oncology molecular-diagnostics strategy during 2025. The company announced a collaboration with SOPHiA GENETICS to develop a global liquid-biopsy companion diagnostic solution for pharmaceutical clinical programs and precision-oncology initiatives. The partnership combines Myriad's U.S. laboratory capabilities with SOPHiA GENETICS' international network and AI-driven precision-medicine technology.
These developments reflect a broader U.S. trend toward combining molecular testing, liquid biopsy, artificial intelligence, and clinical data to deliver more precise cancer diagnosis and treatment monitoring.
Market Segmentation
The Oncology Molecular Diagnostic Market is segmented according to technology, cancer type, application, end user, and region.
Among technology categories, Next-Generation Sequencing (NGS) represents a major growth area because of its ability to analyze multiple genetic alterations simultaneously. NGS-based testing is increasingly used for tumor profiling, biomarker identification, companion diagnostics, and treatment selection.
By cancer type, breast cancer, lung cancer, colorectal cancer, prostate cancer, and other major cancer categories represent important areas of demand. Molecular profiling is particularly valuable in cancers where targeted therapies are linked to specific genomic mutations.
By application, cancer screening and early detection, diagnosis, treatment selection, and treatment monitoring represent the principal opportunities. The development of liquid-biopsy technologies is particularly important for expanding non-invasive monitoring applications.
Oncology Molecular Diagnostic Market Key Players are:
• Abbott Laboratories
• Bayer Healthcare AG
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• Cepheid, Inc.
• Danaher Corporation
• Hologic, Inc.
• Leica Biosystems Inc.
• Qiagen NV
• Roche Diagnostics (Schweiz) AG
• Siemens Healthineers
• Sysmex Corporation
• F-Hoffmann La-Roche Ltd
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• bioMerieux SA
• Veracyte, Inc
• Agilient Technologies, Inc. (Dako)
• TBG Diagnostics Limited
• HTG Molecular Diagnostics, Inc.
Competitive Analysis
The competitive landscape includes major diagnostic, biotechnology, life-science, and healthcare technology companies developing molecular testing platforms, sequencing technologies, companion diagnostics, and precision-oncology solutions. Because the publicly accessible MMR information does not provide verifiable individual percentage shares for the five largest companies, exact company market-share figures are not assigned.
Roche remains an important participant in oncology diagnostics through its molecular testing and companion-diagnostic ecosystem. Its portfolio supports biomarker identification and treatment-selection applications across several cancer types.
Thermo Fisher Scientific continues to strengthen its oncology molecular-diagnostics capabilities through sequencing, molecular biology, and clinical research technologies. Its broad NGS ecosystem provides laboratories with tools for genomic profiling and biomarker analysis.
Illumina remains a major sequencing technology provider supporting oncology research and clinical testing. The continued expansion of comprehensive genomic profiling creates opportunities for sequencing-based oncology diagnostics.
Qiagen provides molecular testing technologies used for cancer biomarker analysis and companion-diagnostic applications. Its portfolio spans sample preparation, molecular assays, and related diagnostic workflows.
Myriad Genetics is increasingly focused on precision oncology and liquid-biopsy applications. Its 2025 collaboration with SOPHiA GENETICS demonstrates the industry's movement toward combining laboratory testing with AI-enabled genomic interpretation and decentralized testing networks.
Beyond established companies, emerging innovators are attracting substantial investment. In January 2025, Tethis received a €15 million investment to develop liquid-biopsy cancer diagnostics integrating sample preparation, nanomaterials, and artificial intelligence.
Regional Analysis
The United States represents a major growth center for oncology molecular diagnostics because of its large oncology research base, advanced laboratory infrastructure, strong pharmaceutical industry, and demand for precision medicine. Regulatory development around molecular diagnostics and liquid biopsy is also supporting innovation. FDA research programs are examining biomarker validation, liquid biopsy, multiomic biomarkers, and methods for monitoring treatment resistance.
Japan offers opportunities because of its advanced healthcare infrastructure, aging population, established pharmaceutical industry, and increasing adoption of precision medicine. Molecular testing can support more targeted approaches to cancer diagnosis and treatment.
China represents another significant opportunity because of its large patient population, expanding biotechnology industry, growing diagnostic infrastructure, and increasing investment in genomic medicine. The expansion of precision-oncology research and molecular testing capabilities is expected to support long-term demand.
Germany, France, and the United Kingdom are also important European markets because of their advanced healthcare systems, cancer research institutions, and growing focus on personalized medicine and biomarker-driven therapies.
Conclusion
The Oncology Molecular Diagnostic Market is positioned for sustained expansion as cancer treatment increasingly moves toward precision medicine, biomarker-guided therapies, comprehensive genomic profiling, and non-invasive molecular monitoring.
In our view, the strongest opportunities will come from next-generation sequencing, liquid biopsy, companion diagnostics, ctDNA analysis, multiomic testing, artificial intelligence, and integrated bioinformatics platforms. The ability to detect molecular changes earlier and monitor treatment response more efficiently will remain a key competitive advantage.
Investment in liquid biopsy is particularly promising because it can expand molecular testing beyond traditional tissue biopsies and create new applications in early detection, minimal residual disease monitoring, recurrence surveillance, and therapy selection. Companies capable of combining highly sensitive molecular technologies with AI-powered interpretation, scalable laboratory workflows, and strong clinical validation will be well positioned to benefit from the long-term growth of precision oncology.
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.
Contact Maximize Market Research
MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? sales@maximizemarketresearch.com
